33.67
-0.93 (-2.70%)
| Previous Close | 34.60 |
| Open | 34.50 |
| Volume | 514,362 |
| Avg. Volume (3M) | 537,182 |
| Market Cap | 1,698,793,088 |
| Price / Earnings (TTM) | 240.47 |
| Price / Earnings (Forward) | 476.19 |
| Price / Sales | 7.57 |
| Price / Book | 5.90 |
| 52 Weeks Range | |
| Earnings Date | 31 Jul 2025 |
| Profit Margin | 1.25% |
| Operating Margin (TTM) | -24.32% |
| Diluted EPS (TTM) | 0.050 |
| Quarterly Revenue Growth (YOY) | 2.60% |
| Quarterly Earnings Growth (YOY) | 52.40% |
| Total Debt/Equity (MRQ) | 33.72% |
| Current Ratio (MRQ) | 5.01 |
| Operating Cash Flow (TTM) | 57.56 M |
| Levered Free Cash Flow (TTM) | -22.77 M |
| Return on Assets (TTM) | -0.45% |
| Return on Equity (TTM) | 1.13% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Vericel Corporation | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -0.5 |
| Average | 1.38 |
|
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.06% |
| % Held by Institutions | 107.99% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Geneva Capital Management Llc | 30 Jun 2025 | 1,784,927 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 67.00 (Stephens & Co., 99.01%) | Buy |
| Median | 62.50 (85.65%) | |
| Low | 58.00 (Canaccord Genuity, 72.28%) | Buy |
| Average | 62.50 (85.65%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 38.61 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 01 Aug 2025 | 58.00 (72.28%) | Buy | 35.63 |
| Stephens & Co. | 16 Jun 2025 | 67.00 (99.01%) | Buy | 41.59 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 Aug 2025 | Announcement | Vericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025 |
| 31 Jul 2025 | Announcement | Vericel Reports Second Quarter 2025 Financial Results |
| 17 Jul 2025 | Announcement | Vericel to Report Second-Quarter 2025 Financial Results on July 31, 2025 |
| 10 Jun 2025 | Announcement | Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |